Vantage Reports
Drawing on Evaluate data, Vantage reports provide an in-depth view on trends in the biotech, pharma and medtech sectors. Our special reports also provide a detailed look at some of the industry's hottest topics.
ESMO 2022 eBook
The European Society of Medical Oncology Conference (ESMO) in Paris has wrapped up and there was much to talk about as Europe’s top oncologists came together to announce…
PD(L)anner – September 2022
Once again, Evaluate Vantage provides the latest insights and expert perspectives on new developments in the PD-(L)1 inhibitor landscape. The last few months have been…
Medtech Infographic: The only way is up - or is it?
As we venture into the second half of 2022, has the medtech market hit its lowest ebb? Will the slump continue or are there a few flickers of light on the horizon, if you…
Pharma Infographic: The only way is up - or is it?
In a world awash with information, Evaluate is here to provide clarity with best-in-class data and expert insight. As we come to the end of a very rocky first…
Biopharma, Biotech and Medtech in Q2: The only way is up or is it?
The first half of 2022 is behind us and for most in the industry, it was a six month period to forget. Have we hit the bottom, or will we plummet still further in the…
Access Valuable Insights Payer Behaviour Infographic
During early-stage development, it has become more critical than ever to factor in payer perspectives and reimbursement dynamics. For a clearer understanding of the payer…
Medtech - Going steady
The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including…
安定に向かう？医療機器セクター eBook 英語版
医療機器セクターは、医薬品市場全体と同様、厳しい状況に置かれています。しかし、デジタル化の進展や新しいタイプのリキッドバイオプシーの出現など、いくつかの興味深い展開が見られます。 本eBook 英語版では、2028年までの最新のコンセンサス予測を含め、医療機器セクター課題について考察しています。 「Evaluate Vantage…
Pharma Drivers Ebook Part 2: Ch-ch-changes
2028-2029 will see some of the biggest blockbusters on the market lose their exclusivity with up to $115bn of sales at risk across those two years. Realistically, of…
